Leucyl-L-Isoleucine.
Two branched-chain amino acids joined together. Once swallowed it splits back into leucine and isoleucine, the pair your muscle draws on to build and repair protein.
- Category
- Compound
What Leucyl-L-Isoleucine is, and what it does.
- Does it work
- Suits people already taking branched-chain amino acids who want a peptide-bound form. Most of what's known comes from peptide absorption biochemistry, not trials of this dipeptide.
- How much to take
- No dose figure is on record for this dipeptide. Start with what the label states, around a meal or a training session, when demand for amino acids is highest.
- Time to feel it
- Blood amino acids rise within about an hour of a dose. Nobody has measured how long any training effect takes with this dipeptide specifically.
- The first dose
- Day one is quiet. The change is in your blood amino acid curve, which climbs within the hour and settles again over the next few.
- With regular use
- Weeks of daily use keep leucine available for muscle protein building. That shows up in training numbers and body composition over months rather than as a sensation.
- How well tolerated
- Amino acids from protein are well tolerated at food-level amounts. Anyone with kidney or liver concerns should check with a doctor first.
- How it feels
- Slightly bitter, the way branched-chain aminos usually are. The effect itself sits in recovery and training over time rather than in an immediate feeling.
- The overlooked benefit
- Peptide-bound amino acids ride their own transporter, separate from the one free amino acids use, so they arrive without queuing behind the free forms.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Intact dipeptide uptake across the intestinal brush borderIn vitro study
- Leucine supply for muscle protein synthesis signallingMeta-analysis
- Branched-chain amino acid intake around trainingRandomised trial
- Effects of the intact dipeptide itself in peopleNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Hydrolysis of the dipeptide delivers free leucine, so the two are the same input arriving by different routes. The dipeptide route uses PEPT1 and can load faster, while free leucine uses amino acid transporters that saturate at high single doses. Anyone counting total leucine in a formula needs to count both.
Valine shares the LAT1 transporter and the branched-chain aminotransferase step with leucine and isoleucine. Loading leucine and isoleucine without valine drives valine levels down over time, which is the reason branched-chain products are conventionally balanced rather than leucine-only. This is a ratio question, not a dose question.
The first committed step in disposing of leucine and isoleucine cannot run without PLP. If the cofactor is short, the transamination step limits how fast a branched-chain load clears. This is a requirement for normal metabolism, not a reason to expect a benefit from extra B6 in someone whose status is already adequate.
The second step of branched-chain catabolism, oxidative decarboxylation of the keto acids, depends on thiamine pyrophosphate along with lipoate, FAD and NAD. Without it the keto acids accumulate rather than being oxidised. This is textbook pathway biochemistry and applies to any branched-chain amino acid load.
FAD is required at several points after the keto acids are decarboxylated. Riboflavin status therefore sits underneath branched-chain oxidation in the same way it sits underneath fatty acid oxidation. It is a permissive requirement rather than a lever to push.
A small fraction of leucine is converted through alpha-ketoisocaproate to HMB. Supplying leucine, whether free or peptide-bound, increases the substrate available for that conversion, though the conversion rate is low and variable. Taking both means one input arrives as precursor and one already downstream of the conversion step.
Taking a fast-absorbing dipeptide alongside casein blunts the speed advantage, because gastric emptying then governs delivery for both. If the point of using a peptide form is a rapid rise in plasma branched-chain amino acids, pairing it with a slow protein works against that. This is a formulation timing issue rather than a chemical interaction.
Nothing specific on file for Leucyl-L-Isoleucine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Leucyl-L-Isoleucine actually does.
Two-amino-acid chains like this one get absorbed intact across the gut wall through a dedicated transporter, a separate route from the one that carries single free amino acids, which is why a paired dose can show up in blood faster than the same amount of free amino acids.
Once inside the gut cell, the pair gets split apart by internal enzymes into free leucine and isoleucine, so what actually reaches the bloodstream is overwhelmingly the two separate free amino acids, not the intact pair.
Leucine is the branched-chain amino acid that switches on a key growth-signaling pathway in cells, while isoleucine contributes to the same amino acid pool but sends a much weaker signal along that pathway.
Both amino acids are broken down by the same first two enzymes, which need vitamin B6 and thiamine along with other cofactors, so loading up on one branched-chain amino acid competes with the others at that shared step.
Where Leucyl-L-Isoleucine comes from.
Two branched-chain amino acids stuck together. Your gut makes this kind of fragment every time you digest protein, and it gets broken back down into the two free amino acids almost immediately.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Fermentation-derived free amino acids for synthesis, or dairy, soy or wheat protein for enzymatic routes.
Chemical synthesis uses a protected leucine activated with a carbodiimide or uronium reagent and coupled to isoleucine. The enzymatic route uses proteases and peptidases under limited hydrolysis, which yields a mixed dipeptide pool rather than a single species.
Reversed-phase or ion-exchange separation, since the isomeric dipeptides of branched-chain amino acids are chemically very similar.
HPLC with mass confirmation. Diastereomeric purity matters because L-isoleucine has two stereocentres and the D-allo forms are common contaminants.
Sold mainly as an analytical standard. Standalone consumer supply is uncommon.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.